Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo

Retrovirology

Volumn 4, Issue , 2007, Pages

  Gorry, Paul R ^a,b,c   McPhee, Dale A ^b,c,e   Verity, Erin ^a,d,e   Dyer, Wayne B ^f,g   Wesselingh, Steven L ^a,b,c   Learmont, Jennifer ^f   Sullivan, John S ^f,g   Roche, Michael ^a   Zaunders, John J ^h   Gabuzda, Dana ^i,j   Crowe, Suzanne M ^a,c   Mills, John ^a   Lewin, Sharon R ^c,k   Brew, Bruce J ^h   Cunningham, Anthony L ^l   Churchill, Melissa J ^a  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^g University of Sydney   (Australia)

^h ST VINCENT S HOSPITAL   (Australia)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k ALFRED HOSPITAL   (Australia)

^l WESTMEAD HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIGEN P24; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; G PROTEIN COUPLED RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; NEF PROTEIN; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIBODY RESPONSE; AUSTRALIA; BLOOD TRANSFUSION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE DELETION; HELPER CELL; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOGENICITY; IN VIVO STUDY; INFECTION CONTROL; LENTIVIRINAE; LONG TERMINAL REPEAT; LYMPHOCYTE PROLIFERATION; MALE; OUTCOME ASSESSMENT; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMATE; RECEPTOR OCCUPANCY; REVIEW; SURVIVAL RATE; VIRUS ATTENUATION; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS VIRULENCE; WESTERN BLOTTING; ARTICLE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PATHOGENICITY; STATISTICS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES;

COHORT STUDIES; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV LONG-TERM SURVIVORS; HIV-1; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SEQUENCE DELETION;

EID: 36048974619     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-4-66     Document Type: Review

References (100)

1. Duerr A Wasserheit JN Corey L HIV vaccines: New frontiers in vaccine development Clin Infect Dis 2006, 43(4);500-511 10.1086/505979 16838241
2. Letvin NL Progress and obstacles in the development of an AIDS vaccine Nat Rev Immunol 2006, 6(12);930-939 10.1038/nri1959 17124514
3. McMichael AJ HIV vaccines Annu Rev Immunol 2006, 24:227-255 10.1146/ annurev.immunol.24.021605.090605 16551249
4. Mathers CD Loncar D Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med 2006, 3(11):e442 1664601 17132052 10.1371/journal.pmed.0030442
5. Chinen J Shearer WT Molecular virology and immunology of HIV infection J Allergy Clin Immunol 2002, 110(2);189-198 10.1067/mai.2002.126226 12170257
6. Letvin NL Walker BD Immunopathogenesis and immunotherapy in AIDS virus infections Nat Med 2003, 9(7):861-866 10.1038/nm0703-861 12835706
7. Spearman P Current progress in the development of HIV vaccines Curr Pharm Des 2006, 12(9)1147-1167 10.2174/138161206776055859 16515492
8. McMichael AJ Hanke T HIV vaccines 1983-2003 Nat Med 2003, 9(7):874-880 10.1038/nm0703-874 12835708
9. Flynn NM Forthal DN Harro CD Judson FN Mayer KH Para MF Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection J Infect Dis 2005, 191(5);654-665 10.1086/428404 15688278
10. Gilbert PB Ackers ML Berman PW Francis DP Popovic V Hu DJ Heyward WL Sinangil F Shepherd BE Gurwith M HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine J Infect Dis 2005, 192(6):974-983 10.1086/ 432734 16107949
11. Gilbert PB Peterson ML Follmann D Hudgens MG Francis DP Gurwith M Heyward WL Jobes DV Popovic V Self SG Sinangil F Burke D Berman PW Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial J Infect Dis 2005, 191(5):666-677 10.1086/ 428405 15688279
12. Graham BS Mascola JR Lessons from failure--preparing for future HIV-1 vaccine efficacy trials J Infect Dis 2005, 191(5):647-649 10.1086/428406 15688276
13. Pantaleo G Koup RA Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know Nat Med 2004, 10(8):806-810 10.1038/nm0804-806 15286782
14. Whitney JB Ruprecht RM Live attenuated HIV vaccines: Pitfalls and prospects Curr Opin Infect Dis 2004, 17(1):17-26 10.1097/ 00001432-200402000-00004 15090885
15. Singh M No vaccine against HIV yet - are we not perfectly equipped? Virol J 2006, 3:60 1563999 16939652 10.1186/1743-422X-3-60
16. Klase Z Donio MJ Blauvelt A Marx PA Jeang KT Smith SM A peptide-loaded dendritic cell based cytotoxic T-lymphocyte (CTL) vaccination strategy using peptides that span SIV Tat, Rev, and Env overlapping reading frames Retrovirology 2006, 3:1 1360091 16398928 10.1186/1742-4690-3-1
17. Mosca JD Chang YN Williams G Antigen-presenting particle technology using inactivated surface-engineered viruses: Induction of immune responses against infectious agents Retrovirology 2007, 4:32 1885814 17504532 10.1186/1742-4690-4-32
18. Wyand MS Manson K Montefiori DC Lifson JD Johnson RP Desrosiers RC Protection by live, attenuated simian immunodeficiency virus against heterologous challenge J Virol 1999, 73(10):8356-8363 112853 10482586
19. Wyand MS Manson KH Garcia-Moll M Montefiori D Desrosiers RC Vaccine protection by a triple deletion mutant of simian immunodeficiency virus J Virol 1996, 70(6);3724-3733 190248 8648707
20. Daniel MD Kirchhoff F Czajak SC Sehgal PK Desrosiers RC Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene Science 1992, 258:5090-1938 1941 10.1126/science.1470917 1470917
21. Almond N Kent K Cranage M Rud E Clarke B Stott EJ Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells Lancet 1995, 345:8961-1342 1344 10.1016/ S0140-6736(95)92540-6 7752758
22. Baba TW Liska V Hofmann-Lehmann R Vlasak J Xu W Ayehunie S Cavacini LA Posner MR Katinger H Stiegler G Bernacky BJ Rizvi TA Schmidt R Hill LR Keeling ME Lu Y Wright JE Chou TC Ruprecht RM Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection Nat Med 2000, 6(2);200-206 10.1038/72309 10655110
23. Ferrantelli F Rasmussen RA Buckley KA Li PL Wang T Montefiori DC Katinger H Stiegler G Anderson DC McClure HM Ruprecht RM Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies J Infect Dis 2004, 189(12):2167-2173 10.1086/ 420833 15181562
24. Mascola JR Lewis MG Stiegler G Harris D VanCott TC Hayes D Louder MK Brown CR Sapan CV Frankel SS Lu Y Robb ML Katinger H Birx DL Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies J Virol 1999, 73(5);4009-4018 104180 10196297
25. Mascola JR Stiegler G VanCott TC Katinger H Carpenter CB Hanson CE Beary H Hayes D Frankel SS Birx DL Lewis MG Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies Nat Med 2000, 6(2);207-210 10.1038/ 72318 10655111
26. Sawai ET Hamza MS Ye M Shaw KE Luciw PA Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef J Virol 2000, 74(4):2038-2045 111683 10644378 10.1128/JVI.74.4.2038-2045.2000
27. Hofmann-Lehmann R Vlasak J Williams AL Chenine AL McClure HM Anderson DC O'Neil S Ruprecht RM Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation Aids 2003, 17(2);157-166 10.1097/00002030-200301240-00004 12545074
28. Churchill M Sterjovski J Gray L Cowley D Chatfield C Learmont J Sullivan JS Crowe SM Mills J Brew BJ Wesselingh SL McPhee DA Gorry PR Longitudinal analysis of nef/long terminal repeat-deleted HIV-1 in blood and cerebrospinal fluid of a long-term survivor who developed HIV-associated dementia J Infect Dis 2004, 190(12):2181-2186 10.1086/ 425585 15551218
29. Churchill MJ Rhodes DI Learmont JC Sullivan JS Wesselingh SL Cooke IR Deacon NJ Gorry PR Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source J Virol 2006, 80(2):1047-1052 1346882 16379007 10.1128/JVI.80.2.1047-1052.2006
30. Learmont JC Geczy AF Mills J Ashton LJ Raynes-Greenow CH Garsia RJ Dyer WB McIntyre L Oelrichs RB Rhodes DI Deacon NJ Sullivan JS Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort N Engl J Med 1999, 340(22):1715-1722 10.1056/NEJM199906033402203 10352163
31. Birch MR Learmont JC Dyer WB Deacon NJ Zaunders JJ Saksena N Cunningham AL Mills J Sullivan JS An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC) J Clin Virol 2001, 22(3):263-270 10.1016/S1386-6532(01)00198-6 11564591
32. Deacon NJ Tsykin A Solomon A Smith K Ludford-Menting M Hooker DJ McPhee DA Greenway AL Ellett A Chatfield C Lawson VA Crowe S Maertz S Sonza S Learmont J Sullivan JS Cunningham A Dwyer D Dowton D Mills J Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients Science 1995, 270(5238):988-991 10.1126/ science.270.5238.988 7481804
33. Kirchhoff F Greenough TC Brettler DB Sullivan JL Desrosiers RC Brief report: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection N Engl J Med 1995, 332(4):228-232 10.1056/ NEJM199501263320405 7808489
34. Kondo M Shima T Nishizawa M Sudo K Iwamuro S Okabe T Takebe Y Imai M Identification of attenuated variants of HIV-1 circulating recombinant form 01Æ that are associated with slow disease progression due to gross genetic alterations in the nef/long terminal repeat sequences Journal of Infectious Diseases 2005, 192:56-61 10.1086/430739 15942894
35. Mariani R Kirchhoff F Greenough TC Sullivan JL Desrosiers RC Skowronski J High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection J Virol 1996, 70(11);7752-7764 190845 8892896
36. Rhodes DI Ashton L Solomon A Carr A Cooper D Kaldor J Deacon N Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian Long-Term Nonprogressor Study Group J Virol 2000, 74(22);10581-10588 110932 11044102 10.1128/JVI.74.22.10581-10588.2000
37. Salvi R Garbuglia AR Di Caro A Pulciani S Montella F Benedetto A Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor J Virol 1998, 72(5):3646-3657 109585 9557645
38. Learmont J Tindall B Evans L Cunningham A Cunningham P Wells J Penny R Kaldor J Cooper DA Long-term symptomless HIV-1 infection in recipients of blood products from a single donor Lancet 1992 340 8824 863 867 10.1016/0140-6736(92)93281-Q 1357294
39. Gorry PR Churchill M Learmont J Cherry C Dyer WB Wesselingh SL Sullivan JS Replication-dependent pathogenicity of attenuated, nef-deleted HIV-1 in vivo. Journal of Acquired Immune Deficiency Syndromes 2007 In press.
40. Verity E Zotos D Wilson K Chatfield C Lawson VA Dwyer D Cunningham A Learmont J Dyer W Sullivan J Churchill M Wesselingh SL Gabuzda D Gorry PR McPhee D Viral phenotypes and antibody responses in long term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef/long terminal repeat region J Virol 2007, 81:9268-9278 10.1128/JVI.00650-07 17567690
41. Gorry PR Bristol G Zack JA Ritola K Swanstrom R Birch CJ Bell JE Bannert N Crawford K Wang H Schols D De Clercq E Kunstman K Wolinsky SM Gabuzda D Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity J Virol 2001, 75(21):10073-10089 114582 11581376 10.1128/JVI.75.21.10073-10089.2001
42. Rhodes D Solomon A Bolton W Wood J Sullivan J Learmont J Deacon N Identification of a new recipient in the Sydney Blood Bank Cohort: A long-term HIV type 1-infected seroindeterminate individual AIDS Res Hum Retroviruses 1999, 15(16):1433-1439 10.1089/088922299309946 10555106
43. Etemad-Moghadam B Sun Y Nicholson EK Fernandes M Liou K Gomila R Lee J Sodroski J Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo J Virol 2000, 74(9):4433-4440 111962 10756060 10.1128/ JVI.74.9.4433-4440.2000
44. Gray L Sterjovski J Churchill M Ellery P Nasr N Lewin SR Crowe SM Wesselingh S Cunningham AL Gorry PR Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome Virology 2005, 337:384-398 10.1016/j.virol.2005.04.034 15916792
45. Crowe SM Ho DD Marriott D Brew B Gorry PR Sullivan JS Learmont J Mills J In vivo replication kinetics of a nef-deleted strain of HIV-1 Aids 2005, 19(8);842-843 10.1097/01.aids.0000168984.05209.f1 15867504
46. Perelson AS Essunger P Cao Y Vesanen M Hurley A Saksela K Markowitz M Ho DD Decay characteristics of HIV-1-infected compartments during combination therapy Nature 1997, 387(6629):188-191 10.1038/387188a0 9144290
47. Perelson AS Neumann AU Markowitz M Leonard JM Ho DD HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time Science 1996, 271(5255):1582-1586 10.1126/ science.271.5255.1582 8599114
48. Wei X Ghosh SK Taylor ME Johnson VA Emini EA Deutsch P Lifson JD Bonhoeffer S Nowak MA Hahn BH Viral dynamics in human immunodeficiency virus type 1 infection Nature, 1995, 373(6510):117-122 10.1038/373117a0 7529365
49. Wu H Kuritzkes DR McClernon DR Kessler H Connick E Landay A Spear G Heath-Chiozzi M Rousseau F Fox L Spritzler J Leonard JM Lederman MM Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points J Infect Dis 1999, 179(4):799-807 10.1086/314670 10068574
50. Gray L Churchill MJ Sterjovski J Witlox K Learmont J Sullivan JS Wesselingh SL Gabuzda D Cunningham AL McPhee DA Gorry PR Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long term survivors infected from a single source Virology Journal 2007, 4(75):1939844-17634131 10.1186/1743-422X-4-75
51. Jekle A Schramm B Jayakumar P Trautner V Schols D De Clercq E Mills J Crowe SM Goldsmith MA Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence J Virol 2002, 76(14):6966-6973 136331 12072497 10.1128/JVI.76.14.6966-6973.2002
52. Gorry PR McPhee DA Wesselingh SL Churchill MJ Macrophage tropism and cytopathicity of HIV-1 variants isolated sequentially from a long-term survivor infected with nef-deleted virus. The Open Microbiology Journal 2007, 1:1-7
53. Gorry PR Taylor J Holm GH Mehle A Morgan T Cayabyab M Farzan M Wang H Bell JE Kunstman K Moore JP Wolinsky SM Gabuzda D Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate Journal of Virology 2002, 76(12):6277-6292 136234 12021361 10.1128/JVI.76.12.6277-6292.2002
54. Ohagen A Ghosh S He J Huang K Chen Y Yuan M Osathanondh R Gartner S Shi B Shaw G Gabuzda D Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope Journal of Virology 1999, 73(2):897-906 103909 9882290
55. Peters PJ Bhattacharya J Hibbitts S Dittmar MT Simmons G Bell J Simmonds P Clapham PR Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages J Virol 2004, 78(13);6915-6926 421670 15194768 10.1128/JVI.78.13.6915-6926.2004
56. Zaunders JJ Geczy AF Dyer WB McIntyre LB Cooley MA Ashton LJ Raynes-Greenow CH Learmont J Cooper DA Sullivan JS Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4+ and CD8+ T lymphocytes: Increased CD45RO+CD4+ T lymphocytes and limited activation of CD8+ T lymphocytes AIDS Res Hum Retroviruses 1999, 15(17):1519-1527 10.1089/088922299309801 10580402
57. Chun TW Chadwick K Margolick J Siliciano RF Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI J Virol 1997, 71(6):4436-4444 191662 9151834
58. Harouse JM Gettie A Tan RC Blanchard J Cheng-Mayer C Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs Science, 1999 284(5415):816-819 10.1126/science.284.5415.816 10221916
59. Lapenta C Parlato S Spada M Santini SM Rizza P Logozzi M Proietti E Belardelli F Fais S Human lymphoblastoid CD4(+) T cells become permissive to macrophage-tropic strains of human immunodeficiency virus type 1 after passage into severe combined immunodeficient mice through in vivo upregulation of CCR5: In vivo dynamics of CD4(+) T-cell differentiation in pathogenesis of AIDS J Virol 1998, 72(12):10323-10327 110622 9811784
60. Schnittman SM Lane HC Greenhouse J Justement JS Baseler M Fauci AS Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: Evidence for a role in the selective T-cell functional defects observed in infected individuals Proc Natl Acad Sci U S A 1990, 87(16):6058-6062 54471 2385584 10.1073/pnas.87.16.6058
61. Kelleher AD Zaunders JJ Decimated or missing in action: CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection Curr HIV/AIDS Rep 2006, 3(1):5-12 10.1007/s11904-006-0002-5 16522253
62. Zaunders JJ Cunningham PH Kelleher AD Kaufmann GR Jaramillo AB Wright R Smith D Grey P Vizzard J Carr A Cooper DA Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia J Infect Dis 1999, 180(2):320-329 10.1086/314880 10395845
63. O'Brien SJ Moore JP The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS Immunol Rev 2000, 177:99-111 10.1034/j.1600-065X.2000.17710.x 11138790
64. Roger M Influence of host genes on HIV-1 disease progression Faseb J 1998, 12(9):625-632 9619442
65. Hazenberg MD Hamann D Schuitemaker H Miedema F T cell depletion in HIV-1 infection: How CD4+ T cells go out of stock Nat Immunol 2000, 1(4):285-289 10.1038/79724 11017098
66. McCune JM The dynamics of CD4+ T-cell depletion in HIV disease Nature 2001, 410(6831):974-979 10.1038/35073648 11309627
67. Alexander L Illyinskii PO Lang SM Means RE Lifson J Mansfield K Desrosiers RC Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys J Virol 2003, 77(12):6823-6835 156171 12768002 10.1128/ JVI.77.12.6823-6835.2003
68. Churchill MJ Figueiredo A Cowley D Gray L Purcell DF Sullivan JS McPhee DA Wesselingh SL Brew BJ Gorry PR Transcriptional activity of blood-and cerebrospinal fluid-derived nef/long-terminal repeat sequences isolated from a slow progressor infected with nef-deleted human immunodeficiency virus type 1 (HIV-1) who developed HIV-associated dementia J Neurovirol 2006, 12(3);219-228 10.1080/13550280600827369 16877303
69. Jeeninga RE Hoogenkamp M Armand-Ugon M de Baar M Verhoef K Berkhout B Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G J Virol 2000, 74(8);3740-3751 111883 10729149 10.1128/ JVI.74.8.3740-3751.2000
70. Gorry P Purcell D Howard J McPhee D Restricted HIV-1 infection of human astrocytes: Potential role of nef in the regulation of virus replication Journal of Neurovirology 1998, 4(4):377-386 9718129
71. Shioda T Oka S Xin X Liu H Harukuni R Kurotani A Fukushima M Hasan MK Shiino T Takebe Y Iwamoto A Nagai Y In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120: Association of V2 extension with slow disease progression J Virol 1997, 71(7):4871-4881 191717 9188549
72. Wang B Spira TJ Owen S Lal RB Saksena NK HIV-1 strains from a cohort of American subjects reveal the presence of a V2 region extension unique to slow progressors and non-progressors Aids 2000, 14(3);213-223 10.1097/ 00002030-200002180-00002 10716496
73. Iversen AK Shpaer EG Rodrigo AG Hirsch MS Walker BD Sheppard HW Merigan TC Mullins JI Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual J Virol 1995, 69(9):5743-5753 189435 7637019
74. Alexander L Aquino-DeJesus MJ Chan M Andiman WA Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child J Virol 2002, 76(20);10533-10539 136583 12239333 10.1128/ JVI.76.20.10533-10539.2002
75. Binley JM Jin X Huang Y Zhang L Cao Y Ho DD Moore JP Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression J Virol 1998, 72(4):3472-3474 109859 9525685
76. Wang B Ge YC Palasanthiran P Xiang SH Ziegler J Dwyer DE Randle C Dowton D Cunningham A Saksena NK Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispecies in blood and plasma Virology 1996, 223(1);224-232 10.1006/viro.1996.0471 8806556
77. Yamada T Iwamoto A Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection Arch Virol 2000, 145(5);1021-1027 10.1007/s007050050692 10881687
78. Michael NL Chang G d'Arcy LA Ehrenberg PK Mariani R Busch MP Birx DL Schwartz DH Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus J Virol 1995, 69(7):4228-4236 189160 7769682
79. Hua J Caffrey JJ Cullen BR Functional consequences of natural sequence variation in the activation domain of HIV-1 Rev Virology 1996, 222(2);423-429 10.1006/viro.1996.0439 8806526
80. Smith SM Pentlicky S Klase Z Singh M Neuveut C Lu CY Reitz MS Jr. Yarchoan R Marx PA Jeang KT An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection J Biol Chem 2003, 278(45):44816-44825 10.1074/jbc.M307546200 12947089
81. Churchill M Chiavaroli L Wesselingh SL Gorry PR Persistence of attenuated HIV-1 rev alleles in an epidemiologically linked cohort of long-term survivors infected with nef-deleted virus Retrovirology 2007, 4:43 1933581 17601342 10.1186/1742-4690-4-43
82. Adalid-Peralta L Grangeot-Keros L Rudent A Ngo-Giang-Huong N Krzysiek R Goujard C Deveau C Le Gall M Meyer L Emilie D Rouzioux C Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection HIV Med 2006, 7(8):514-519 10.1111/j.1468-1293.2006.00406.x 17105510
83. Wilson KM Johnson EI Croom HA Richards KM Doughty L Cunningham PH Kemp BE Branson BM Dax EM Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations Aids 2004, 18(17):2253-2259 10.1097/00002030-200411190-00005 15577537
84. Carotenuto P Looij D Keldermans L de Wolf F Goudsmit J Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection Aids 1998, 12(13):1591-1600 10.1097/00002030-199813000-00005 9764777
85. Pilgrim AK Pantaleo G Cohen OJ Fink LM Zhou JY Zhou JT Bolognesi DP Fauci AS Montefiori DC Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection J Infect Dis 1997, 176(4);924-932 9333150
86. Zhang YJ Fracasso C Fiore JR Bjorndal A Angarano G Gringeri A Fenyo EM Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors J Infect Dis 1997, 176(5):1180-1187 9359717
87. Cranage MP Whatmore AM Sharpe SA Cook N Polyanskaya N Leech S Smith JD Rud EW Dennis MJ Hall GA Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa Virology 1997, 229(1):143-154 10.1006/viro.1996.8419 9123856
88. Enose Y Ui M Miyake A Suzuki H Uesaka H Kuwata T Kunisawa J Kiyono H Takahashi H Miura T Hayami M Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV Virology 2002, 298 (2):306-316 10.1006/ viro.2002.1440 12127792
89. Igarashi T Ami Y Yamamoto H Shibata R Kuwata T Mukai R Shinohara K Komatsu T Adachi A Hayami M Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: A potential candidate live-attenuated human AIDS vaccine J Gen Virol 1997, 78(Pt 5):985-989 9152414
90. Kumar A Mukherjee S Shen J Buch S Li Z Adany I Liu Z Zhuge W Piatak M Jr. Lifson J McClure H Narayan O Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus Virology 2002, 301(2):189-205 10.1006/ viro.2002.1544 12359422
91. Montefiori DC Baba TW Li A Bilska M Ruprecht RM Neutralizing and infection-enhancing antibody responses do not correlate with the differential pathogenicity of SIVmac239delta3 in adult and infant rhesus monkeys J Immunol 1996, 157(12):5528-5535 8955203
92. Stipp HL Kumar A Narayan O Characterization of immune escape viruses from a macaque immunized with live-virus vaccine and challenged with pathogenic SHIVKU-1 AIDS Res Hum Retroviruses 2000, 16(15):1573-1580 10.1089/088922200750006092 11054270
93. Greenough TC Somasundaran M Brettler DB Hesselton RM Alimenti A Kirchhoff F Panicali D Sullivan JL Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection AIDS Res Hum Retroviruses 1994, 10(4):395-403 8068417
94. Qiao X He B Chiu A Knowles DM Chadburn A Cerutti A Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells Nat Immunol 2006, 7(3):302-310 10.1038/ni1302 16429138
95. Pontesilli O Klein MR Kerkhof-Garde SR Pakker NG de Wolf F Schuitemaker H Miedema F Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection J Infect Dis 1998, 178(4):1008-1018 9806028
96. Riviere Y McChesney MB Porrot F Tanneau-Salvadori F Sansonetti P Lopez O Pialoux G Feuillie V Mollereau M Chamaret S Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS AIDS Res Hum Retroviruses 1995, 11(8):903-907 7492437
97. Geldmacher C Currier JR Herrmann E Haule A Kuta E McCutchan F Njovu L Geis S Hoffmann O Maboko L Williamson C Birx D Meyerhans A Cox J Hoelscher M CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients J Virol 2007, 81(5):2440-2448 1865944 17182686 10.1128/JVI.01847-06
98. Dyer WB Ogg GS Demoitie MA Jin X Geczy AF Rowland-Jones SL McMichael AJ Nixon DF Sullivan JS Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1 J Virol 1999, 73(1):436-443 103850 9847349
99. Dyer WB Geczy AF Kent SJ McIntyre LB Blasdall SA Learmont JC Sullivan JS Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection Aids 1997, 11(13);1565-1574 10.1097/00002030-199713000-00004 9365760
100. Dyer WB Kuipers H Coolen MW Geczy AF Forrester J Workman C Sullivan JS Correlates of antiviral immune restoration in acute and chronic HIV type 1 infection: sustained viral suppression and normalization of T cell subsets AIDS Res Hum Retroviruses 2002, 18(14):999-1010 10.1089/ 08892220260235362 12396452